TY - JOUR
T1 - The prognostic potential of human prostate cancer-associated macrophage subtypes as revealed by single-cell transcriptomics
AU - Siefert, Joseph C.
AU - Cioni, Bianca
AU - Muraro, Mauro J.
AU - Alshalalfa, Mohammed
AU - Vivie, Judith
AU - van der Poel, Henk G.
AU - Schoots, Ivo G.
AU - Bekers, Elise
AU - Feng, Felix Y.
AU - Wessels, Lodewyk F.A.
AU - Zwart, Wilbert
AU - Bergman, Andries M.
N1 - Funding Information:
F.Y. Feng reports personal fees from Janssen, Blue Earth Diagnostics, Astellas, Myovant, Roivant, Genentech, Bayer, PFS Genomics, SerImmune, and Bristol-Myers Squibb outside the submitted work. L.F.A. Wessels reports grants from Genmab BV during the conduct of the study. W. Zwart reports grants from Astellas Pharma outside the submitted work. A.M. Bergman reports grants from FP7 MCA-ITN and KWF Dutch Cancer Society during the conduct of the study. No disclosures were reported by the other authors.
Publisher Copyright:
2021 The Authors; Published by the American Association for Cancer Research
PY - 2021/10
Y1 - 2021/10
N2 - Macrophages in the tumor microenvironment are causally linked with prostate cancer development and progression, yet little is known about their composition in neoplastic human tissue. By performing single cell transcriptomic analysis of human prostate cancer resident macrophages, three distinct populations were identified in the diseased prostate. Unexpectedly, no differences were observed between macrophages isolated from the tumorous and nontumorous portions of the prostatectomy specimens. Markers associated with canonical M1 and M2 macrophage phenotypes were identifiable, however these were not the main factors defining unique subtypes. The genes selectively associated with each macrophage cluster were used to develop a gene signature which was highly associated with both recurrence-free and metastasis-free survival. These results highlight the relevance of tissue-specific macrophage subtypes in the tumor microenvironment for prostate cancer progression and demonstrates the utility of profiling single-cell transcriptomics in human tumor samples as a strategy to design gene classifiers for patient prognostication. Implications: The specific macrophage subtypes present in a diseased human prostate have prognostic value, suggesting that the relative proportions of these populations are related to patient outcome. Understanding the relative contributions of these subtypes will not only inform patient prognostication, but will enable personalized immunotherapeutic strategies to increase beneficial populations or reduce detrimental populations.
AB - Macrophages in the tumor microenvironment are causally linked with prostate cancer development and progression, yet little is known about their composition in neoplastic human tissue. By performing single cell transcriptomic analysis of human prostate cancer resident macrophages, three distinct populations were identified in the diseased prostate. Unexpectedly, no differences were observed between macrophages isolated from the tumorous and nontumorous portions of the prostatectomy specimens. Markers associated with canonical M1 and M2 macrophage phenotypes were identifiable, however these were not the main factors defining unique subtypes. The genes selectively associated with each macrophage cluster were used to develop a gene signature which was highly associated with both recurrence-free and metastasis-free survival. These results highlight the relevance of tissue-specific macrophage subtypes in the tumor microenvironment for prostate cancer progression and demonstrates the utility of profiling single-cell transcriptomics in human tumor samples as a strategy to design gene classifiers for patient prognostication. Implications: The specific macrophage subtypes present in a diseased human prostate have prognostic value, suggesting that the relative proportions of these populations are related to patient outcome. Understanding the relative contributions of these subtypes will not only inform patient prognostication, but will enable personalized immunotherapeutic strategies to increase beneficial populations or reduce detrimental populations.
UR - http://www.scopus.com/inward/record.url?scp=85117757098&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-20-0740
DO - 10.1158/1541-7786.MCR-20-0740
M3 - Article
C2 - 34131070
AN - SCOPUS:85117757098
SN - 1541-7786
VL - 19
SP - 1778
EP - 1791
JO - Molecular Cancer Research
JF - Molecular Cancer Research
IS - 10
ER -